12:00 AM
 | 
Sep 17, 2012
 |  BC Week In Review  |  Company News  |  Deals

ImaginAb, MacroGenics deal

The companies partnered to develop in vivo imaging agents for autoimmune diseases and cancer. ImaginAb will develop a clinical imaging agent based on an undisclosed MacroGenics' anti-CD3 antibody as a patient selection tool for ongoing clinical programs....

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >